As a clinical academic I divide my time equally between clinical stroke care (at University College Hospital and The National Hospital for Neurology and Neurosurgery, Queen Square) and academic commitments at the Stroke Research Centre, UCL Institute of Neurology. My major research interest is in the clinical an pathophysiological implications of cerebral small vessel disease (the commonest known brain disorder). My focus is on intracranial (including intracerebral) haemorrhage, which is the most devastating type of stroke. I have expertise in observational studies and neuroimaging including magnetic resonance imaging (MRI). I lead a research programme including observational, genetic and neuroimaging studies of subarachnoid haemorrhage and intracerebral haemorrhage, with particular expertise in cerebral amyloid angiopathy. I was Chief Investigator for the Clinical Relevance of Microbleeds in Stroke (CROMIS-2) study: www.ucl.ac.uk/cromis-2 and the Geneticand Observational Subarachnoid Haemorrhage (GOSH) Study.  I was Chief investigator for the Biomarkers in Cerebral Amyloid Angiopathy (BOCAA) at UCL. I was UK Chief investigator for a therapeutic trial of the monoclonal antibody Ponezumab in Cerebral Amyloid Angiopathy. In collaboration with Prof Peter Rothwell (Oxford) I am Co-Chief Investigator for a randomised controlled trial of blood pressure lowering after intracerebral haemorrhage (Prevention Of Hypertensive Injury to the Brain - Intracerebral haemorrhage: PROHIBIT-ICH) funded by the Stroke Association.  I am Chief Investigator of the BHF-funded OPTIMAS (Optimal Timing of Anticoagulation in Stroke) trial, currently running at over 60 hospitals in the UK. I am lead for the Microbleeds International Collaborative Network (MICON). I am Principal Investigator for numerous collaborative National Institute of Health Research (NIHR)-funded stroke research studies and am Speciality Lead for Stroke in the NIHR Clinical Research Network: North Thames.  I am a member of Trial Steering Committees for NIHR multi-centre studies including TICH-3(Tranexamic Acid in Intracerebral Haemorrhage), R4VaD (Risks, Rates and Routes to Reduce Vascular Dementia), LACI-2 (Lacunar Intervention) and Remote Ischaemic Conditioning After Stroke (RECAST-3), Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST).